Effects of telmisartan on the level of Aβ1-42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer's disease

National Medical Journal of China

Volumn 92, Issue 39, 2012, Pages 2743-2746

  Li, Wei ^a   Zhang, Jie Wen ^a   Lu, Fen ^a   Ma, Ming Ming ^a   Wang, Jiang Qiao ^a   Suo, Ai Qin ^a   Bai, Ying Ying ^a   Liu, Hui Qin ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Alzheimer's disease; Amyloid ; Interleukin 1; Telmisartan; Tumor necrosis factor

Indexed keywords

AMLODIPINE; AMYLOID BETA PROTEIN[1-42]; INTERLEUKIN 1BETA; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; HUMAN; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PATIENT ASSESSMENT; RATING SCALE; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMLODIPINE; AMYLOID BETA-PEPTIDES; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; COGNITION; FEMALE; HUMANS; HYPERTENSION; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PPAR GAMMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872150780     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2012.39.003     Document Type: Article

References (27)

1. Selkoe D J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev, 2001, 81: 741-766.
2. LaFerla F M, Green K N, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci, 2007, 8: 499-509.
3. Britschgi M, Wyss-Coray T. Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol, 2007, 82: 205-233.
4. Querfurth H W, LaFerla F M. Alzheimer's disease. N Engl J Med, 2010, 362: 329-344.
5. Li R, Beebe T, Cui J, et al. Pulsatile shear stress increased mitochondrial membrane potential: implication of Mn-SOD. Biochem Biophys Res Commun, 2009, 388: 406-412.
6. Sato T, Hanyu H, Hirao K, et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging, 2011, 32: 1626-1633.
7. Birkenhager W H, Staessen J A. Blood pressure and dementia. Panminerva Med, 2004, 46: 227-237.
8. Mielke M M, Rosenberg P B, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology, 2007, 69: 1850-1858.
9. Roselli F, Tartaglione B, Federico F, et al. Rate of MMSE score change in Alzheimer's disease: influence of education and vascular risk factors. Clin Neurol Neurosurg, 2009, 111: 327-330.
10. 2007, 15: 969-971.
11. 2011, 91, 940-945.
12. Jiang Q, Heneka M, Landreth G E. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs, 2008, 22: 1-14.
13. Watson G S, Cholerton B A, Reger M A, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry, 2005, 13: 950-958.
14. Spies P E, Verbeek M M, van Groen T, et al. Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer. Front Biosci, 2012, 17: 2024-2034.
15. Perrin R J, Craig-Schapiro R, Malone J P, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One, 2011, 6: e16032.
16. 2003, 19: 41-44.
17. Neumann K F, Rojo L, Navarrete L P, et al. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Gun Alzheimer Res, 2008, 5: 438-447.
18. Heneka M T, Sastre M, Dumitrescu-Ozimek L, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain, 2005, 128: 1442-1453.
19. McGeer E G, McGeer P L. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmaeol Biol Psychiatry, 2003, 27: 741-749.
20. Griffin W S, Mrak R E. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol, 2002, 72: 233-238.
21. Bonotis K, Krikki E, Holeva V, et al. Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol, 2008, 193: 183-187.
22. Lombardi V R, Garcia M, Rey L, et al.Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J Neuroimmunol, 1999, 97: 163-171.
23. Combs C K, Johnson D E, Karlo J C, et al. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci, 2000, 20: 558-567.
24. Sastre M, Dewachter I, Rossner S, et al. Nonsteroidal antiinflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA, 2006, 103: 443-448.
25. Tsukuda K, Mogi M, Iwanami J, et al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension, 2009, 54: 782-787.
26. Washida K, Ihara M, Nishio K, et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke, 2010, 41: 1798-1806.
27. Mogi M, Li J M, Tsukuda K, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun, 2008, 375: 446-449.